In this cohort study of 5714 men with PCa and 28 445 men without PCa, men with type 2 diabetes and PCa who received a GnRH agonist had 53% higher risk of an increase in CVD risk compared with men with type 2 diabetes and PCa who did not receive a GnRH agonist. Here, GNRH1 is linked to type 2 diabetes mellitus.